HUP0102101A3
(en)
|
1997-11-10 |
2002-11-28 |
Bristol Myers Squibb Co |
Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
|
AU5438499A
(en)
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
WO2000012485A1
(en)
|
1998-08-29 |
2000-03-09 |
Astrazeneca Ab |
Pyrimidine compounds
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
EP2308833A3
(de)
|
1999-04-15 |
2011-09-28 |
Bristol-Myers Squibb Company |
Zyklische Proteintyrosinkinaseinhibitoren
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
US6797706B1
(en)
|
1999-06-09 |
2004-09-28 |
Yamanouchi Pharmaceutical Co., Ltd. |
Heterocyclecarboxamide derivative
|
WO2000076980A1
(fr)
*
|
1999-06-10 |
2000-12-21 |
Yamanouchi Pharmaceutical Co., Ltd. |
Nouveaux derives heterocycliques azotes ou leurs sels
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
WO2001025220A1
(en)
|
1999-10-07 |
2001-04-12 |
Amgen Inc. |
Triazine kinase inhibitors
|
ATE314362T1
(de)
*
|
1999-10-12 |
2006-01-15 |
Takeda Pharmaceutical |
Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
|
AU1941501A
(en)
*
|
1999-11-30 |
2001-06-12 |
Parker Hughes Institute |
Syk localized at centrosome
|
HUP0301117A3
(en)
|
2000-02-17 |
2004-01-28 |
Amgen Inc Thousand Oaks |
Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
KR100711042B1
(ko)
*
|
2000-04-28 |
2007-04-24 |
다나베 세이야꾸 가부시키가이샤 |
환상 화합물
|
US7273868B2
(en)
*
|
2000-04-28 |
2007-09-25 |
Tanabe Seiyaku Co., Ltd. |
Pyrazine derivatives
|
US20080027037A1
(en)
*
|
2000-04-28 |
2008-01-31 |
Tanabe Seiyaku Co., Ltd. |
Cyclic compounds
|
JP2001302667A
(ja)
*
|
2000-04-28 |
2001-10-31 |
Bayer Ag |
イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
|
ES2559273T3
(es)
|
2000-05-08 |
2016-02-11 |
Janssen Pharmaceutica Nv |
Profármacos de pirimidinas que inhiben la replicación del VIH
|
WO2001085700A2
(en)
*
|
2000-05-08 |
2001-11-15 |
Janssen Pharmaceutica N.V. |
Hiv replication inhibiting pyrimidines and triazines
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7183288B2
(en)
*
|
2001-11-01 |
2007-02-27 |
Herwig Josephus Margareta Janssen, legal representative |
Amide derivatives as glycogen synthase kinase 3-β inhibitors
|
ES2419164T3
(es)
*
|
2001-11-02 |
2013-08-19 |
The Regents Of The University Of California |
Composiciones para la prevención y el tratamiento de una enfermedad inflamatoria, una enfermedad autoinmune, y rechazo de trasplante
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
RU2343148C2
(ru)
*
|
2002-02-01 |
2009-01-10 |
Райджел Фармасьютикалз, Инк |
Соединения 2,4-пиримидиндиаминов и их применение
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003208479A1
(en)
|
2002-03-09 |
2003-09-22 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US7176310B1
(en)
*
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
ES2373226T3
(es)
*
|
2002-06-28 |
2012-02-01 |
Astellas Pharma Inc. |
Derivado de diaminopirimidincarboxamida.
|
EP2316459B1
(de)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
|
DK1534286T3
(da)
|
2002-07-29 |
2010-04-26 |
Rigel Pharmaceuticals Inc |
Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
|
EP1542989B1
(de)
*
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
CA2542007C
(en)
*
|
2002-10-09 |
2010-06-29 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
AU2003302893A1
(en)
*
|
2002-12-06 |
2004-06-30 |
The Trustees Of Boston University |
METHODS FOR SUSTAINING eNOS ACTIVITY
|
AU2003293833B2
(en)
*
|
2002-12-12 |
2009-10-01 |
Covis Pharma B.V. |
Combination medicament
|
AU2003289330A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Kyowa Hakko Kogyo Co., Ltd. |
Preventives and/or remedies for central diseases
|
US20040242613A1
(en)
*
|
2003-01-30 |
2004-12-02 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pyrimidine derivatives useful as inhibitors of PKC-theta
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
US7459460B2
(en)
*
|
2003-05-28 |
2008-12-02 |
Bristol-Myers Squibb Company |
Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
PT1656372E
(pt)
|
2003-07-30 |
2013-06-27 |
Rigel Pharmaceuticals Inc |
Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
|
ATE506953T1
(de)
*
|
2003-08-07 |
2011-05-15 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
NZ585188A
(en)
*
|
2003-08-15 |
2011-09-30 |
Novartis Ag |
2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
JP5618452B2
(ja)
*
|
2003-09-16 |
2014-11-05 |
タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングTakeda GmbH |
呼吸器疾患の治療のためのシクレソニドの使用
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
US8057815B2
(en)
*
|
2004-04-19 |
2011-11-15 |
Portola Pharmaceuticals, Inc. |
Methods of treatment with Syk inhibitors
|
EP1740188A1
(de)
*
|
2004-04-20 |
2007-01-10 |
Altana Pharma AG |
Verwendung von ciclesonid zur behandlung von atemwegserkrankungen eines rauchenden patienten
|
JP2008505910A
(ja)
*
|
2004-07-08 |
2008-02-28 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
Pkc−シータのインヒビターとして有用なピリミジン誘導体
|
EP1791538A1
(de)
*
|
2004-09-10 |
2007-06-06 |
Altana Pharma AG |
Roflumilast- und syk-inhibitorkombination und verfahren zur verwendung dafür
|
CA2579007A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Altana Pharma Ag |
Ciclesonide and syk inhibitor combination and methods of use thereof
|
US7557207B2
(en)
|
2004-11-24 |
2009-07-07 |
Rigel Pharmaceuticals, Inc. |
Spiro 2,4-pyrimidinediamine compounds and their uses
|
CA2589793A1
(en)
*
|
2004-12-17 |
2006-06-22 |
Astrazeneca Ab |
4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
NZ556761A
(en)
*
|
2005-01-25 |
2011-04-29 |
Galenea Corp |
Substituted arylamine compounds and their use as 5-HT6 modulators
|
AR054336A1
(es)
*
|
2005-03-30 |
2007-06-20 |
Astion Dev As |
Tratamiento de enfermedades dermatologicas y del prurito
|
US20060270694A1
(en)
*
|
2005-05-03 |
2006-11-30 |
Rigel Pharmaceuticals, Inc. |
JAK kinase inhibitors and their uses
|
WO2007028445A1
(en)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
AR054834A1
(es)
*
|
2005-07-15 |
2007-07-18 |
Glaxo Group Ltd |
Derivados de 1,1-dioxido-2,3-dihidro-1,2-benzoisotiazol-6-il-1h-indazol-4-il-2,4 pirimidina diamina
|
MX2008001428A
(es)
*
|
2005-07-30 |
2008-04-04 |
Astrazeneca Ab |
Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
|
KR20080049130A
(ko)
|
2005-09-30 |
2008-06-03 |
아스트라제네카 아베 |
세포 증식 억제 활성을 갖는 이미다조 [1,2-a] 피리딘
|
MY167260A
(en)
*
|
2005-11-01 |
2018-08-14 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
TW200811169A
(en)
*
|
2006-05-26 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
MX2009000769A
(es)
*
|
2006-07-21 |
2009-01-28 |
Novartis Ag |
Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
|
CN101616895A
(zh)
|
2006-12-08 |
2009-12-30 |
Irm责任有限公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
AU2008215948A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
WO2015164330A1
(en)
|
2014-04-21 |
2015-10-29 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2728893C
(en)
*
|
2008-04-16 |
2017-03-14 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk protein kinase
|
PL2321283T3
(pl)
*
|
2008-04-16 |
2017-01-31 |
Portola Pharmaceuticals, Inc. |
2,6-diaminopirymidyn-5-ylokarboksamidy jako inhibitory kinaz syk lub jak
|
MX2010011463A
(es)
|
2008-04-16 |
2011-06-03 |
Portola Pharm Inc |
2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
|
MY155639A
(en)
*
|
2008-04-16 |
2015-11-13 |
Portola Pharm Inc |
2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
|
SI2300013T1
(en)
|
2008-05-21 |
2018-03-30 |
Adriad Pharmacaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US8338439B2
(en)
*
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
DK2361248T3
(en)
|
2008-06-27 |
2019-01-14 |
Celgene Car Llc |
Heteroberl compounds and uses thereof
|
EP3023426A1
(de)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
WO2010033248A2
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
EP2361902A4
(de)
*
|
2008-11-21 |
2012-04-25 |
Astellas Pharma Inc |
4,6-diaminonicotinsäureamidverbindung
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
WO2010097248A1
(en)
*
|
2009-01-13 |
2010-09-02 |
Glaxo Group Limited |
Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
TW201040162A
(en)
|
2009-05-06 |
2010-11-16 |
Portola Pharm Inc |
Inhibitors of JAK
|
US8586751B2
(en)
|
2009-06-12 |
2013-11-19 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
TW201105669A
(en)
*
|
2009-07-30 |
2011-02-16 |
Irm Llc |
Compounds and compositions as Syk kinase inhibitors
|
KR101246911B1
(ko)
*
|
2009-11-02 |
2013-03-25 |
한국화학연구원 |
신규한 2,4-피리미딘 유도체 및 이의 용도
|
WO2011065800A2
(ko)
*
|
2009-11-30 |
2011-06-03 |
주식회사 오스코텍 |
피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
|
EP2516434B1
(de)
*
|
2009-12-23 |
2015-05-27 |
Takeda Pharmaceutical Company Limited |
Geschmolzene heteroaromatische pyrrolidinone als syk-hemmer
|
EP2542536B1
(de)
|
2010-03-04 |
2015-01-21 |
Cellzome Limited |
Morpholinsubstituierte Harnstoff-Derivate als mTOR-Hemmer
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
JP6060071B2
(ja)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚および線維症適用におけるrna干渉
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
EP3144298A1
(de)
|
2010-08-10 |
2017-03-22 |
Celgene Avilomics Research, Inc. |
Besylatsalz aus einem btk-hemmer
|
US8580805B2
(en)
*
|
2010-08-31 |
2013-11-12 |
Hubert Maehr |
Pyrimidine carboxamide derivatives
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
MX2013004894A
(es)
|
2010-11-01 |
2013-10-17 |
Celgene Avilomics Res Inc |
Compuestos heterociclicos y usos de los mismos.
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
AU2016244228B2
(en)
*
|
2011-04-22 |
2019-02-21 |
Signal Pharmaceuticals, Llc |
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
JP6027095B2
(ja)
|
2011-04-22 |
2016-11-16 |
シグナル ファーマシューティカルズ,エルエルシー |
置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法
|
JP5999177B2
(ja)
|
2011-05-04 |
2016-09-28 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
EP2707357B1
(de)
|
2011-05-10 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Pyridylaminopyrimidine als syk-hemmer
|
MX2013013090A
(es)
|
2011-05-10 |
2013-12-16 |
Merck Sharp & Dohme |
Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
|
EP2706852B1
(de)
|
2011-05-10 |
2018-08-22 |
Merck Sharp & Dohme Corp. |
Bipyridylaminopyridine als syk-hemmer
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
BR112014000360A2
(pt)
|
2011-07-28 |
2017-02-14 |
Cellzome Ltd |
análogos de heterociclil pirimidina como inibidores jak
|
RU2564419C1
(ru)
*
|
2011-07-28 |
2015-09-27 |
Целльзом Лимитид |
Гетероциклические аналоги пиримидина в качестве ингибиторов jak
|
EP2758379B1
(de)
|
2011-09-21 |
2016-10-19 |
Cellzome Limited |
Harnstoff- und Carbamatderivate des 2-Morpholino-1,3,5-Triazins als mTOR Inhibitoren zur Behandlung von immunologischen oder proliferative Erkrankungen
|
US9145414B2
(en)
|
2011-09-30 |
2015-09-29 |
Taiho Pharmaceutical Co., Ltd. |
1,2,4-triazine-6-carboxamide derivative
|
WO2013052393A1
(en)
|
2011-10-05 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
|
US9006444B2
(en)
|
2011-10-05 |
2015-04-14 |
Merck Sharp & Dohme Corp. |
Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
|
EP2763976B1
(de)
|
2011-10-05 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
2-pyridyl-carboxamid-haltige milztyrosinkinase-hemmer
|
AU2012320465B2
(en)
|
2011-10-07 |
2016-03-03 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
CA2856306A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Portola Pharmaceuticals, Inc. |
Selective kinase inhibitors
|
AU2012340555B2
(en)
|
2011-11-23 |
2016-10-20 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
RU2576623C2
(ru)
*
|
2011-12-28 |
2016-03-10 |
Фуджифилм Корпорэйшн |
Новое производное никотинамида или его соль
|
MX356179B
(es)
|
2012-03-15 |
2018-05-17 |
Celgene Avilomics Res Inc |
Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
|
JP6317319B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の固体形態
|
EA201491748A1
(ru)
|
2012-03-23 |
2015-02-27 |
Дзе Юниверсити Оф Квинсленд |
Иммуномодулирующие средства и способы их применения
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
US20130310387A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
|
US9487504B2
(en)
|
2012-06-20 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Imidazolyl analogs as syk inhibitors
|
EP2863916B1
(de)
|
2012-06-22 |
2018-07-18 |
Merck Sharp & Dohme Corp. |
Substituierte pyridin-milz-tyrosinkinaseinhibitoren
|
US9416111B2
(en)
|
2012-06-22 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
|
WO2014031438A2
(en)
*
|
2012-08-20 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
|
WO2014048065A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Triazolyl derivatives as syk inhibitors
|
US10112928B2
(en)
*
|
2012-10-19 |
2018-10-30 |
Hoffmann-La Roche Inc. |
Inhibitors of SYK
|
US9624210B2
(en)
|
2012-12-12 |
2017-04-18 |
Merck Sharp & Dohme Corp. |
Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
|
EP2935226A4
(de)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
Heteroarylverbindungen und verwendungen davon
|
US9598405B2
(en)
|
2012-12-21 |
2017-03-21 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
|
CN104870437A
(zh)
*
|
2013-01-17 |
2015-08-26 |
四川恒康发展有限责任公司 |
三嗪化合物、其药用盐、异构体或水合物及其药物组合物
|
CN105188371A
(zh)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk抑制剂及其用途
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9745295B2
(en)
|
2013-04-26 |
2017-08-29 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
WO2014176216A1
(en)
|
2013-04-26 |
2014-10-30 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
CN113151180A
(zh)
|
2013-12-02 |
2021-07-23 |
菲奥医药公司 |
癌症的免疫治疗
|
JP6883987B2
(ja)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
CN105960404B
(zh)
|
2013-12-05 |
2019-09-03 |
药品循环有限责任公司 |
布鲁顿氏酪氨酸激酶的抑制剂
|
WO2015094997A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
EP3083559B1
(de)
|
2013-12-20 |
2021-03-10 |
Merck Sharp & Dohme Corp. |
Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer
|
WO2015095444A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
WO2015138273A1
(en)
|
2014-03-13 |
2015-09-17 |
Merck Sharp & Dohme Corp. |
2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
ES2741785T3
(es)
|
2014-08-13 |
2020-02-12 |
Celgene Car Llc |
Formas y composiciones de un inhibidor de ERK
|
KR20230037676A
(ko)
|
2014-09-05 |
2023-03-16 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
ES2882954T3
(es)
|
2014-12-16 |
2021-12-03 |
Signal Pharm Llc |
Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel
|
NZ732793A
(en)
|
2014-12-16 |
2023-07-28 |
Signal Pharm Llc |
Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
|
EP3250557A4
(de)
|
2015-01-29 |
2018-06-20 |
Signal Pharmaceuticals, LLC |
Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
|
WO2016168444A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Purdue Research Foundation Office Of Technology Commercialization |
Methods for treating hemolytic diseases and sickle cell disease
|
AU2016270658B2
(en)
|
2015-05-29 |
2021-08-12 |
Alexion Pharmaceuticals, Inc. |
Cerdulatinib for the treatment of B-cell malignancies
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
KR20180026739A
(ko)
|
2015-07-06 |
2018-03-13 |
알엑스아이 파마슈티칼스 코포레이션 |
슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
|
JP6805232B2
(ja)
|
2015-07-24 |
2020-12-23 |
セルジーン コーポレイション |
(1r,2r,5r)−5−アミノ−2−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
JP6944936B2
(ja)
|
2015-12-04 |
2021-10-06 |
ポートラ ファーマシューティカルズ, インコーポレイテッド |
血液癌を処置するためのセルデュラチニブ
|
WO2018002311A1
(en)
|
2016-06-30 |
2018-01-04 |
Siess Wolfgang |
Treatment and prevention of atherothrombosis by inhibition of syk kinase
|
GB201807845D0
(en)
*
|
2018-05-15 |
2018-06-27 |
Univ Manchester |
Kinase Inhibitors
|
US20230002766A1
(en)
|
2019-11-08 |
2023-01-05 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
|
EP4085136A1
(de)
|
2019-12-31 |
2022-11-09 |
Phio Pharmaceuticals Corp. |
Chemisch modifizierte oligonukleotide mit verbesserter systemischer abgabe
|
KR20240041973A
(ko)
|
2021-08-04 |
2024-04-01 |
피오 파마슈티칼스 코프. |
화학적으로 변형된 올리고뉴클레오티드
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|